• enVVeno Medical received U.S. Patent No. 12,575,932 covering core elements of its enVVe transcatheter replacement venous valve system.
• Patent protection targets technology for treating deep venous insufficiency, a condition linked to reflux, venous hypertension, and venous leg ulcers.
• Milestone strengthens IP position ahead of the TAVVE U.S. pivotal trial under an FDA IDE; enrollment is expected to start soon.
• Initial patient data from the pivotal study is expected by the end of Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607070829ACCESSWRNAPR_____1187037) on July 07, 2026, and is solely responsible for the information contained therein.